Loading…
Rhythm Pharmaceuticals, Inc. is projected to rise to $128.70 by 2027, a +19% move from its current price of $108.40. RYTM is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/13/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 14 | $105.86 | $108.44 | $111.08 | +0.04% |
| Jul 15 | $104.85 | $108.48 | $112.23 | +0.07% |
| Jul 16 | $104.09 | $108.52 | $113.13 | +0.11% |
| Jul 17 | $103.46 | $108.56 | $113.91 | +0.15% |
| Jul 18 | $102.91 | $108.60 | $114.60 | +0.18% |
| Jul 19 | $102.42 | $108.64 | $115.23 | +0.22% |
| Jul 20 | $101.98 | $108.68 | $115.82 | +0.26% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $101.98 | $108.68 | $115.82 | +0.26% |
| Week 2 | $99.58 | $108.95 | $119.21 | +0.51% |
| Week 3 | $97.84 | $109.23 | $121.96 | +0.77% |
| Week 4 | $96.43 | $109.51 | $124.37 | +1.03% |
| Week 5 | $95.23 | $109.79 | $126.58 | +1.28% |
| Week 6 | $94.19 | $110.07 | $128.63 | +1.54% |
| Week 7 | $93.26 | $110.35 | $130.58 | +1.80% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Rhythm Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focusing on rare neuroendocrine diseases in the United States and internationally. Its lead product candidate is IMCIVREE (setmelanotide), a treatment for pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (LEPR) deficiency obesity, Bardet-Biedl and Alström syndrome, Prader-Willi syndrome, and hypothalamic obesity.
The company is in Phase 3 clinical trials for treating acquired hypothalamic obesity, congenital hypothalamic obesity, POMC and LEPR insufficiency obesities, SRC1 deficiency obesity, and SH2B1 deficiency obesity; and in Phase 2 clinical trials for Prader-Willi syndrome and MC4R deficiency obesity. Rhythm was founded in 2008 and is headquartered in Boston, Massachusetts, and was formerly known as Rhythm Metabolic, Inc., changing its name to Rhythm Pharmaceuticals, Inc. in October 2015.
Rhythm Pharmaceuticals, Inc. (RYTM) is a healthcare company with a current price of $114.17 and a market capitalization of $7.83B, ranking 1044. The stock sits in a market position that reflects mid-to-large cap exposure within the sector.
A major floor 33.9% below — a decisive break under it would weaken the trend.
The nearest floor, 22.2% below — buyers have tended to step in here.
The nearest ceiling, 6.5% above — a clean break opens room to run.
A major ceiling 23.5% above — clearing it would confirm fresh momentum.
Key RYTM support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of RYTM market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $112.89 | Sell | $112.00 | Sell |
| MA 10 | $111.99 | Sell | $110.57 | Sell |
| MA 20 | $104.57 | Buy | $105.92 | Buy |
| MA 50 | $95.08 | Buy | $98.52 | Buy |
| MA 100 | $92.17 | Buy | $95.91 | Buy |
| MA 200 | $98.56 | Buy | $93.28 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 58.77 | Neutral |
| Stoch RSI (14) | 0.00 | Buy |
| CCI (20) | 30.94 | Neutral |
| Williams %R (14) | -50.25 | Info |
| MACD (12,26,9) | 0.20 | Buy |
| ROC (12) | 2.08 | Buy |
| Bollinger %B (20,2) | 0.60 | Neutral |
| Stochastic %K (14) | 49.75 | Neutral |
| TRIX (15) | 0.89 | Buy |
| Awesome (5,34) | 15.17 | Buy |
| Ultimate (7,14,28) | 53.51 | Neutral |
| Momentum (10) | 0.14 | Buy |
| Aroon Osc (25) | 96.00 | Buy |
| Hull MA (9) | 113.84 | Sell |
| ADX (14) | 34.62 | Buy |
| ATR (14) | 2.22 | Info |
The 30-day technical picture is bullish, with RSI(14) at 80 and price momentum supported by SMA50 at $92.30 and SMA200 at $98.16. The near-term dynamics show a resistance level at $114.17 and a support level at $84.35, framing a tight trading range above the recent base.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $75.82 | $108.40 | $142.51 | 0% | Neutral | |
| $103.60 | $128.70 | $168.41 | +19% | Neutral | |
| $111.23 | $141.56 | $191.48 | +31% | Bullish | |
| $129.47 | $168.12 | $233.41 | +55% | Bullish | |
| $155.84 | $205.96 | $292.28 | +90% | Bullish | |
| $182.15 | $244.63 | $353.88 | +126% | Bullish | |
| $198.85 | $271.06 | $398.93 | +150% | Bullish | |
| $210.80 | $291.37 | $435.59 | +169% | Bullish | |
| $228.36 | $319.85 | $485.10 | +195% | Bullish | |
| $233.13 | $330.68 | $508.29 | +205% | Bullish | |
| $374.99 | $563.01 | $915.56 | +419% | Bullish | |
| $769.30 | $1,272.02 | $2,246.65 | +10.7x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $75.82 | $108.40 | $130.66 | +0.00% |
| August 2026 | $93.62 | $110.12 | $132.71 | +1.58% |
| September 2026 | $94.69 | $112.06 | $136.41 | +1.77% |
| October 2026 | $97.77 | $116.33 | $142.80 | +3.81% |
| November 2026 | $97.65 | $116.71 | $144.26 | +0.32% |
| December 2026 | $95.45 | $114.55 | $142.51 | -1.85% |
Click any year to see its month-by-month RYTM forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The RYTM price prediction for 2026 points to an average of $108.40 (low $75.82, high $142.51) — a potential gain of 0% on today's $108.40. A consolidation phase looks the most probable path here.
In 2027, RYTM is projected to trade between $103.60 and $168.41, averaging $128.70 — a potential gain of +19% from today's $108.40. That is up +19% on the projected 2026 average. Price action looks broadly range-bound.
Rhythm Pharmaceuticals, Inc.'s 2028 outlook centres on $141.56, within a $111.23 to $191.48 range. That is up +10% on the projected 2027 average. That marks a +31% change versus current levels. Buyers look set to stay in control over this stretch.
By 2029, RYTM could reach as high as $233.41, with a base case around $168.12 and support toward $129.47 — roughly +55% from $108.40. Momentum favours further upside here.
Expect RYTM to range from $155.84 to $292.28 through 2030. The $205.96 average target implies a +90% move from current prices. That is up +23% on the projected 2029 average. Buyers look set to stay in control over this stretch.
The RYTM price prediction for 2031 points to an average of $244.63 (low $182.15, high $353.88) — a potential gain of +126% on today's $108.40. Momentum favours further upside here.
In 2032, RYTM is projected to trade between $198.85 and $398.93, averaging $271.06 — a potential gain of +150% from today's $108.40. That is up +11% on the projected 2031 average. Buyers look set to stay in control over this stretch.
Rhythm Pharmaceuticals, Inc.'s 2033 outlook centres on $291.37, within a $210.80 to $435.59 range. That is up +7% on the projected 2032 average. That marks a +169% change versus current levels. Momentum favours further upside here.
By 2034, RYTM could reach as high as $485.10, with a base case around $319.85 and support toward $228.36 — roughly +195% from $108.40. Buyers look set to stay in control over this stretch.
Expect RYTM to range from $233.13 to $508.29 through 2035. The $330.68 average target implies a +205% move from current prices. That is up +3% on the projected 2034 average. Momentum favours further upside here.
The RYTM price prediction for 2040 points to an average of $563.01 (low $374.99, high $915.56) — a potential gain of +419% on today's $108.40. Buyers look set to stay in control over this stretch.
In 2050, RYTM is projected to trade between $769.30 and $2,246.65, averaging $1,272.02 — a potential gain of +10.7x from today's $108.40. That is up +126% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in RYTM today (≈ 9.225092 RYTM) could be worth
$11,734.51
+$10,734.51 (+1073%) by 2050 · US Dollar
Based on the average projected RYTM price of $1,272.02 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in RYTMwould be worth at today's price.
$1,000 invested in RYTM on Jul 10, 2025 (≈ 11.230907 RYTM) would be worth
$1,217.43
+$217.43 (+21.7%) today · 1.22× · US Dollar
Based on a RYTM entry price of $89.04 vs. today's $108.4.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $114.17 | $949.46 | -5.1% |
| 1 month ago | $85.71 | $1,264.73 | +26.5% |
| 3 months ago | $84.39 | $1,284.51 | +28.5% |
| 6 months ago | $104.89 | $1,033.46 | +3.3% |
| 1 year ago | $89.04 | $1,217.43 | +21.7% |
| All time (5.0y) ago | $18.95 | $5,720.32 | +472.0% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our RYTM forecast.
Our base-case forecast reaches $220.00 around 2031.
Implied market cap at $220.00: $15.09B
Forecasts show a progressive path for Rhythm over the coming years. In 2026, the min is $75.82, the avg is $114.17, and the max is $150.91, with ROI 0 and a Neutral sentiment. By 2027, the avg rises to $140.52 with a max of $182.54 and ROI of 23.1, supported by a Bullish sentiment.
The trajectory continues through 2028 (avg $155.18, max $207.89, ROI 35.9) and 2029 (avg $188.23, max $258.37, ROI 64.9), culminating in 2030 (avg $233.62, max $327.33, ROI 104.6, Bullish). The upward trend extends beyond to 2040 (avg $664.73, max $1,058.85, ROI 482.2) and 2050 (avg $1,529.60, max $2,635.04, ROI 1239.8), with continued Bullish sentiment. These figures illustrate a strong long-term upward trajectory, though they represent estimates and carry inherent uncertainty.
Tap a question to reveal the answer.
The forecast for 2030 shows an average price of $233.62 with a range from $178.61 to $327.33 and an ROI of 104.6%.
Forecasts show bullish sentiment from 2027 onward, with rising averages and ROIs (e.g., 2027 ROI 23.1%, 2028 ROI 35.9%, 2029 ROI 64.9%, 2030 ROI 104.6%). The 2026 forecast is neutral with ROI 0. These numbers are estimates and not guarantees.
Yes. The 2026 forecast lists a max of $150.91, indicating a possible move to about $150.91 within that year.
$7.83B.
Rhythm Pharmaceuticals, Inc. Community Discussion
0Share your Rhythm Pharmaceuticals, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.